Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Has Average Target Price of $21.33 According to Brokerages

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) have earned a consensus recommendation of “Hold” from the five research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.33.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anavex Life Sciences in a research report on Tuesday, September 8th.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: One market report cited a consensus analyst price target of $21.33, substantially above Anavex’s recent trading level. However, the report provided no new operating, clinical, or financial catalyst to support that valuation. Anavex Life Sciences consensus price target report
• Neutral Sentiment: Several firms, including Robbins LLP, Rosen Law Firm, SBS, Pomerantz, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, and others, are soliciting investors who purchased AVXL securities between November 26, 2025, and August 28, 2026. Investors have until November 30, 2026, to seek appointment as lead plaintiff. These notices are primarily legal-service announcements and do not establish that Anavex violated securities laws. Robbins LLP Anavex investor notice Rosen Law Firm Anavex notice
• Negative Sentiment: The lawsuit alleges that Anavex and certain officers violated federal securities laws, while a separate investigation is examining whether directors and officers breached fiduciary duties. If the claims advance, potential damages, legal costs, management distraction, and reputational harm could weigh on AVXL. The concentrated flow of notices likely reinforces near-term bearish sentiment. Kirby McInerney Anavex class action Grabar Law Office Anavex investigation

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in Anavex Life Sciences by 64.7% in the first quarter. Bank of America Corp DE now owns 863,150 shares of the biotechnology company’s stock valued at $2,650,000 after purchasing an additional 338,961 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Anavex Life Sciences during the second quarter worth about $746,000. Renaissance Technologies LLC grew its stake in Anavex Life Sciences by 988.8% during the first quarter. Renaissance Technologies LLC now owns 276,800 shares of the biotechnology company’s stock worth $850,000 after buying an additional 251,378 shares in the last quarter. PVG Asset Management Corp increased its holdings in Anavex Life Sciences by 51.4% in the 1st quarter. PVG Asset Management Corp now owns 327,544 shares of the biotechnology company’s stock valued at $1,006,000 after buying an additional 111,249 shares during the period. Finally, Hikari Power Ltd bought a new position in Anavex Life Sciences in the 2nd quarter valued at about $222,000. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $1.82 on Thursday. The stock’s fifty day moving average price is $2.81 and its two-hundred day moving average price is $2.91. Anavex Life Sciences has a one year low of $1.72 and a one year high of $10.38. The firm has a market cap of $168.71 million, a price-to-earnings ratio of -12.13 and a beta of 1.17.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Tuesday, August 25th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.16. On average, equities analysts anticipate that Anavex Life Sciences will post -0.33 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders. The company’s research centers on small-molecule treatments intended to address disease mechanisms associated with conditions affecting the central nervous system.

Anavex’s lead investigational product is blarcamesine, also known as ANAVEX2-73, an orally administered compound being studied in disorders including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome.